Executive summary
The market is small; the export lever is not
Domestic pharma is a slow-growing base near USD 23 bn in 2025 on a ~2.4% trajectory [Korea Pharma Outlook 2025]. The story sits in exports: medicine exports reached USD 10.4 bn in 2025, up 11.8%, with biologics at 62.6% of the total [KPBMA 2026]. Korea sells capacity and molecules, not its home market.
Two engines, compounding
Biosimilars give Korea a pipeline edge — 5 of 18 US FDA biosimilar approvals in 2025, the most of any country, led by Celltrion and Samsung Bioepis [MDToday 2026]. CDMO gives it scale: Samsung Biologics cleared KRW 4.56 trn revenue and KRW 6 trn in new orders in 2025 [SBL FY25]. The BIOSECURE Act, signed into the FY26 NDAA, hands Korean plants the demand Chinese CDMOs vacate [Lawtimes 2026].
Market size & the export mix: where the growth actually sits
The domestic market is a stable, demographically-driven base. The expansion vector is the bio-export lever — biosimilars plus contract manufacturing — which is where capacity and pipeline decisions earn their return.
Domestic: slow, aging, defensive
Korea's domestic pharma market sits near USD 23 bn in 2025, growing about 2.4% a year toward USD 26 bn by 2030 [Korea Pharma Outlook 2025]. An aging population and broad national insurance support volume, but price control and tendering cap value growth. Oncology and large-molecule biologics are the fastest domestic segments.
Exports: the real engine
Medicine exports hit USD 10.4 bn in 2025, up 11.8%, with biologics at 62.6% of the total [KPBMA 2026]. The mix has shifted hard toward biosimilars and CDMO output. First-half 2025 health exports — pharma, biosimilars, diagnostics — passed USD 13 bn, a fresh record [Korea Health Export 2025].
Innovation, not just volume
In 2025 Korean firms signed technology-transfer deals worth over USD 4.8 bn [Korea Health Export 2025]. Korea increasingly exports the right to make molecules, not only the molecules — a higher-margin layer on top of product shipments.